KALA BIO enters its May 19 Q1 results having lost nearly three-quarters of its value over the past month — a collapse that changes what Monday's print is actually about.
The price action alone frames the setup. The stock closed at $2.93 on Friday, down 26% on the week and 74% over the past month. The sell-off has been violent enough that short sellers have effectively stepped aside: short interest collapsed 90% in the past week to just 1% of the free float. That is not a crowded short. It is a market that has already done much of the damage through outright selling rather than borrowing. Borrow costs have eased alongside — from above 21% in early April to 12.3% now — and availability has loosened as short demand dried up.
The earnings history reinforces the caution. Every one of the past four prints ended with the stock lower. The April 2026 announcement sent shares down 15% on the day and a further 21% over the following five days. The March print fell 14.5% on the day. January's reaction was a milder 2% drop on day one, but shares still shed 18.5% over the following week. The single exception was November 2025, where a 5.8% day-one drop reversed into a 32% gain over the five-day window — though that outlier has not been repeated.
The fundamental picture is what a pre-revenue clinical-stage biotech typically looks like: no revenues, a net loss of roughly $9.8 million, and operating cash outflow near $43 million on an annualised basis. That cash burn is the central question for investors. ORTEX scores show momentum at the bottom of its range — the momentum component has been grinding lower through May — while the value score has improved somewhat as the share price has compressed. Baker Bros. Advisors, a well-regarded healthcare specialist, held 36,000 shares as of year-end and had been adding, but the data is several months old and the recent price move will have materially altered the picture. CEO David Lazar bought $1.8 million of stock in November at $2.00, placing the purchase close to current levels — though that trade is now nearly six months old.
The May 19 print is therefore less about any single quarter's loss figure and more about whether management can provide a credible runway narrative — cash position, clinical milestones, and burn rate guidance — that justifies holding a stock that has already been sold down aggressively.
See the live data behind this article on ORTEX.
Open KALA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
